Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Non-cash Items (2016 - 2025)

Adma Biologics (ADMA) has disclosed Non-cash Items for 11 consecutive years, with $39.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-cash Items fell 42.18% year-over-year to $39.4 million, compared with a TTM value of $39.4 million through Dec 2025, down 42.18%, and an annual FY2025 reading of $39.4 million, down 42.18% over the prior year.
  • Non-cash Items was $39.4 million for Q4 2025 at Adma Biologics, up from $2.8 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $68.1 million in Q4 2024 and bottomed at $35935.0 in Q4 2021.
  • Average Non-cash Items over 5 years is $10.6 million, with a median of $5.7 million recorded in 2022.
  • The sharpest move saw Non-cash Items soared 21161.28% in 2022, then crashed 62.72% in 2025.
  • Year by year, Non-cash Items stood at $35935.0 in 2021, then skyrocketed by 21161.28% to $7.6 million in 2022, then grew by 16.67% to $8.9 million in 2023, then surged by 664.16% to $68.1 million in 2024, then crashed by 42.18% to $39.4 million in 2025.
  • Business Quant data shows Non-cash Items for ADMA at $39.4 million in Q4 2025, $2.8 million in Q3 2025, and $11.1 million in Q2 2025.